

Prescription Drug List Per Act 165 of 2016

Ranking	PRODUCT_NAME	LABELER_NAME	BG_IN D	AVG_PERC ENT_INCR EASE	TOTAL_QU ANTITY	TOTAL_AMOU NT_PAID	List appeared on:
1	VYVANSE	SHIRE US, INC.	B	58.60%	639,728	\$5,473,510.83	5
2	METHYLPHENIDATE HCL ER	WATSON PHARMA, INC.	G	50.14%	615,342	\$4,466,606.97	5
				18.50%			1
3	HUMIRA PEN	ABBVIE INC	B	102.80%	2,806	\$4,978,270.95	5
4	LYRICA	PFIZER, INC	B	105.79%	724,390	\$3,541,871.94	5
				19.77%			1
5	FOCALIN XR	NOVARTIS	B	80.32%	252,509	\$2,846,464.99	5
				15.40%			1
6	ENBREL SURECLICK	AMGEN/IMMUNEX	B	87.95%	2,916	\$2,417,969.47	5
				19.13%			1
7	NOVOLOG FLEXPEN	NOVO NORDISK, INC.	B	94.50%	95,305	\$2,409,488.27	5
				16.43%			1
8	LATUDA	SUNOVION PHARMACEUTICALS, INC	B	95.30%	57,035	\$1,754,771.27	5
				20.76%			1
9	EPIPEN 2-PAK	MYLAN SPECIALTY P.	B	152.89%	4,171	\$1,193,858.28	5
10	NOVOLOG	NOVO NORDISK, INC.	B	94.52%	69,900	\$1,583,541.29	5
				16.43%			1